Esculin attenuates cholestatic liver injury and fibrosis in bile duct-ligated rats by modulating oxidative stress, inflammatory responses, and fibrogenic mediators
It is suggested that esculin exerts hepatoprotective and antifibrotic effects through coordinated modulation of oxidative stress, inflammatory responses, and fibrogenic mediators, as evidenced by reduced NF-κB and TGF-β1 mRNA expression together with decreased LOX activity.
Liver cirrhosis represents the irreversible end‐stage of various chronic liver diseases, whereas hepatic fibrosis, characterized by hepatic stellate cell (HSC) activation, constitutes the critical pathological intermediate in this progression. In this study, we investigated the antifibrotic effects of loganin, a natura...
Xinwen Li, Hui-Ling Zhang, Chao Zhang et al.· Mediators of Inflammation· 0 citations
Cholestatic liver diseases are characterized by disrupted bile acid homeostasis, oxidative stress, and inflammation, ultimately leading to progressive hepatic injury. Although ursodeoxycholic acid (UDCA) remains the standard pharmacological therapy, its therapeutic efficacy is limited in several cholestatic conditions....
Amany M. Hamed, D. Al-Nouri, N. Mahrous et al.· International Journal of Mol...· 0 citations
Background and purpose: Cholestasis or bile duct ligation (BDL) could develop cirrhosis and may lead to other organ dysfunction, including the kidneys, which is called cholemic nephropathy (CN). Hyperbilirubinemia, bile acid accumulation, renal hypoperfusion, oxidative stress, and inflammation are implicated in the pat...
Mohammad Akhbari, Shadan Saberi, Mohammad Khaksari et al.· Research in Pharmaceutical S...· 0 citations
Alcohol-associated liver disease (ALD) represents a major contributor to liver fibrosis globally, and current therapeutic options remain inadequate. The TGF-β/Smad4 cascade is critically involved in alcohol-evoked activation of hepatic stellate cells and subsequent extracellular matrix accumulation. Although Shenze...
Lu Wang, Qian-Yu Gu, Ting-He Jia et al.· Frontiers in Pharmacology· 0 citations